Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.

Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control.

Tesofensine is considered a triple monoamine reuptake inhibitor, which means it prevents the reabsorption of three neurotransmitters — dopamine, serotonin, and noradrenaline — by nerve cells. Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome. See press release here. Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for Tesomet is a combination of two medications — tesofensine and metoprolol.

Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. 2021-03-03 2018-06-07 Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi syndrome, two severe rare disorders characterized by obesity and loss of appetite control. Saniona achieved positive top-line Phase 2 results from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a double-blind trial followed by a 24-week open label extension) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in 2021-03-08 Saniona har fått klartecken av amerikanska läkemedelsmyndigheten FDA att utföra en säkerhetsstudie inom hjärta-kärl som en del av bolagets kliniska utvecklingsprogram för Tesomet inom hypotalamisk fetma. Studien sträcker sig över en kortare period, ett par månader, och inkluderar cirka 300 patienter. Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity. Publicerad: 2021-03-08 (GlobeNewswire) Saniona får återkoppling från FDA gällande den regulatoriska vägen framåt för Tesomet mot hypotalamisk fetma Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) PRESS RELEASE.

March 4, 2021: BioStock article: Saniona´s CMO on the FDA’s Orphan Drug Designation for Tesomet in Prader-Willi Syndrome. Link. February 4, 2021: BioStock article: Saniona's Chief Communications Officer on the importance of communication. Link. January 12, 2021: BioStock article: Saniona's CEO on the plans for 2021. Link.

Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and 2020-04-22 Saniona previously evaluated Tesomet in a randomized, double-blind, placebo-controlled Phase 2a trial in adults and adolescents with PWS. Adult patients receiving Tesomet achieved a statistically significant reduction in hyperphagia, as well as a clinically meaningful reduction in … Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced positive top-line results from the Phase 2 open-label extension study of Tesomet in Saniona has announced results from its 24-week double blind, randomized, placebo-controlled Phase 2 trial evaluating the safety and efficacy of Tesomet in patients with hypothalamic obesity (HO). The study results showed that Tesomet was safe and well tolerated.

The Investor Relations website contains information about Saniona AB - Newsroom's business for stockholders, potential investors, and financial analysts.

Innehavare av TO2 äger rätt att för varje teckningsoption teckna en ny aktie i Saniona till en kurs om 25 SEK per aktie. För BioStock berättar Sanionas vd Rami Levin att befintlig kliniska data pekar på att man kommer att nå marknad med läkemedelskandidaten Tesomet inom två sällsynta ätstörningssjukdomar. 2019-09-24 · Saniona announced that adolescents with Prader-Willi syndrome (PWS) showed improvements in weight, body mass index (BMI), and hyperphagia score — measuring appetite reduction — when treated with the investigational therapy Tesomet in a 24-week, open-label extension of a Phase 2a clinical trial. Läkemedelsbolaget Saniona utvecklar Tesomet, ett läkemedel som i tidigare studier visat sig vara dramatiskt viktminskande. Vi kontaktade Sanionas vice vd Thomas Feldthus för att få veta mera om skillnaderna mellan Tesomet och nuvarande behandlingsalternativ. Fördubblade kostnader för typ 2-diabetes i Sverige på åtta år Saniona får återkoppling från FDA gällande den regulatoriska vägen framåt för Tesomet mot hypotalamisk fetma. Se pressmeddelande här Saniona bjuder in investerare till en presentation av de positiva topline-resultaten från fas 2-studien: Tesomet för behandling av hypotalamisk fetma Publicerad: 2020-04-27 (GlobeNewswire) Saniona is Inviting Investors to Participate to a Presentation of the Positive Topline Results from the Phase 2 Trial: Tesomet for the Treatment of Hypothalamic Obesity 2021-03-03 · Saniona har av det amerikanska läkemedelsverket FDA beviljats särläkemedelsklassning av Tesomet som behandling av Prader-Willis syndrom (PWS).

Saniona is advancing Tesomet for The two main active ingredients in Tesomet are tesofensine and metoprolol. Tesofensine is considered a triple monoamine reuptake inhibitor, which means it prevents the reabsorption of three neurotransmitters — dopamine, serotonin, and noradrenaline — by nerve cells.
Anna stina lannergård

Willis syndrom baserat på positiva resultat hos vuxna patienter. Danska Sanionas fas II-studie med läkemedelskandidaten Tesomet mot hypotalamisk fetma har nyligen publicerats. I studien ingick 21 BioStock: Sanionas vd: momentum för Tesomet i två sällsynta BioStock: Saniona kommenterar den potentiella; Varför två börser i usa.

Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker).
Nytida lon

Saniona har fått klartecken av amerikanska läkemedelsmyndigheten FDA att utföra en säkerhetsstudie inom hjärta-kärl som en del av bolagets kliniska utvecklingsprogram för Tesomet inom hypotalamisk fetma. Studien sträcker sig över en kortare period, ett par månader, och inkluderar cirka 300 patienter.

Sanionas strategiska prioriteringar på kort sikt är följande: About Saniona Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.

Hur ange kontonummer nordea

24 Nov 2020 Saniona: Tesomet Potential Reinforced and that tesomet holds the potential as a potential efficacious treatment in this indication, in our view.

Saniona avancerar Tesomet för behandling av hypotalamisk fetma och Prader-Willis syndrom, två allvarliga och sällsynta störningar som kännetecknas av fetma och störd aptitreglering. Prövningsläkemedlet Tesomet är en fastdoskombination av tesofensin (en trefaldig monoaminåterupptagshämmare) och metoprolol (en beta-1-selektiv blockerare). Saniona avancerar Tesomet för behandling av hypotalamisk fetma och Prader-Willis syndrom, två allvarliga och sällsynta störningar som kännetecknas av fetma och störd aptitreglering.